While emphasizing the company has no guidance on timing of additional trials or data disclosures from partners, Culley said Roche and Genentech have “somewhat suddenly” opened 10 new clinical sites in the GALE Phase 2a surgical optimization study over the last nine months, bringing the trial to 17 locations. He described the acceleration in site openings as a favorable sign that could support preparations for later-stage trials.Chief Executive Officer Brian Culley said the company continues to view OpRegen— ...